|
1
|
Baize N, Monnet I, Greillier L, Quere G,
Kerjouan M, Janicot H, Vergnenegre A, Auliac JB and Chouaid C:
Second-line treatments of small-cell lung cancers. Expert Rev
Anticancer Ther. 17:1033–1043. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Asamura H, Kameya T, Matsuno Y, Noguchi M,
Tada H, Ishikawa Y, Yokose T, Jiang SX, Inoue T, Nakagawa K, et al:
Neuroendocrine neoplasms of the lung: A prognostic spectrum. J Clin
Oncol. 24:70–76. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Metro G, Ricciuti B, Chiari R, Baretti M,
Falcinelli L, Giannarelli D, Sidoni A, Mountzios G, Crinò L,
Bellezza G, et al: Survival outcomes and incidence of brain
recurrence in high-grade neuroendocrine carcinomas of the lung:
Implications for clinical practice. Lung Cancer. 95:82–87. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Travis WD: Advances in neuroendocrine lung
tumors. Ann Oncol. 21 (Suppl 7):vii65–71. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
van Meerbeeck JP, Fennell DA and De
Ruysscher DK: Small-cell lung cancer. Lancet. 378:1741–1755. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rudin CM, Pietanza MC, Bauer TM, Ready N,
Morgensztern D, Glisson BS, Byers LA, Johnson ML, Burris HA III,
Robert F, et al: Rovalpituzumab tesirine, a DLL3-targeted
antibody-drug conjugate, in recurrent small-cell lung cancer: A
first-in-human, first-in-class, open-label, phase 1 study. Lancet
Oncol. 18:42–51. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Saunders LR, Bankovich AJ, Anderson WC,
Aujay MA, Bheddah S, Black K, Desai R, Escarpe PA, Hampl J, Laysang
A, et al: A DLL3-targeted antibody-drug conjugate eradicates
high-grade pulmonary neuroendocrine tumor-initiating cells in vivo.
Sci Transl Med. 7:302ra1362015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gazdar AF, Bunn PA and Minna JD:
Small-cell lung cancer: What we know, what we need to know and the
path forward. Nat Rev Cancer. 17:725–737. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bauer TM, Spigel D, Ready N, Morgensztern
D, Glisson BS, Byers LA, Burris H, Robert F, Strickland DK,
Pietanza MC, Govindan R Dylla SJ, Peng S and Rudin C: ORAL02.01:
Safety and efficacy of single-agent rovalpituzumab tesirine, a
DLL3-targeted ADC, in recurrent or refractory SCLC: Topic: Medical
oncology. J Thorac Oncol. 11:S252–S253. 2016. View Article : Google Scholar
|
|
10
|
Tanaka K, Isse K, Fujihira T, Takenoyama
M, Saunders L, Bheddah S, Nakanishi Y and Okamoto I: Prevalence of
delta-like protein 3 expression in patients with small cell lung
cancer. Lung Cancer. 115:116–120. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sharma SK, Pourat J, Abdel-Atti D, Carlin
SD, Piersigilli A, Bankovich AJ, Gardner EE, Hamdy O, Isse K,
Bheddah S, et al: Noninvasive interrogation of DLL3 expression in
metastatic small cell lung cancer. Cancer Res. 77:3931–3941. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sakaeda M, Sato H, Ishii J, Miyata C,
Kamma H, Shishido-Hara Y, Shimoyamada H, Fujiwara M, Endo T, Tanaka
R, et al: Neural lineage-specific homeoprotein BRN2 is directly
involved in TTF1 expression in small-cell lung cancer. Lab Invest.
93:408–421. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Misch D, Blum T, Boch C, Weiss T, Crolow
C, Griff S, Mairinger T, Bauer TT and Kollmeier J: Value of thyroid
transcription factor (TTF)-1 for diagnosis and prognosis of
patients with locally advanced or metastatic small cell lung
cancer. Diagn Pathol. 10:212015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kitamura H, Yazawa T, Sato H, Okudela K
and Shimoyamada H: Small cell lung cancer: Significance of RB
alterations and TTF-1 expression in its carcinogenesis, phenotype,
and biology. Endocr Pathol. 20:101–107. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mukhopadhyay S and Katzenstein AL:
Subclassification of non-small cell lung carcinomas lacking
morphologic differentiation on biopsy specimens: Utility of an
immunohistochemical panel containing TTF-1, napsin a, p63, and
CK5/6. Am J Surg Pathol. 35:15–25. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cardnell RJ, Li L, Sen T, Bara R, Tong P,
Fujimoto J, Ireland AS, Guthrie MR, Bheddah S, Banerjee U, et al:
Protein expression of TTF1 and cMYC define distinct molecular
subgroups of small cell lung cancer with unique vulnerabilities to
aurora kinase inhibition, DLL3 targeting, and other targeted
therapies. Oncotarget. 8:73419–73432. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Brambilla E, Beasley MB, Austin JHM,
Capelozzi VL, Chirieac LR, Devesa SS, Frank GA, Gazdar A, Ishikawa
Y, Jen J, et al: Small cell carcinoma. WHO classification of tumors
of the lung, pleura, thymus and heart. Travis WD, Brambilla E,
Burke AP, Marx A and Nicholson AG: IARC; Lyon: pp. 62–68. 2015
|
|
18
|
Detterbeck FC, Boffa DJ, Kim AW and Tanoue
LT: The eighth edition lung cancer stage classification. Chest.
151:193–203. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Welti J, Rodrigues DN, Sharp A, Sun S,
Lorente D, Riisnaes R, Figueiredo I, Zafeiriou Z, Rescigno P, de
Bono JS and Plymate SR: Analytical validation and clinical
qualification of a new immunohistochemical assay for androgen
receptor splice variant-7 protein expression in metastatic
castration-resistant prostate cancer. Eur Urol. 70:599–608. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sabari JK, Lok BH, Laird JH, Poirier JT
and Rudin CM: Unravelling the biology of SCLC: Implications for
therapy. Nat Rev Clin Oncol. 14:549–561. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chapman G, Sparrow DB, Kremmer E and
Dunwoodie SL: Notch inhibition by the ligand DELTA-LIKE 3 defines
the mechanism of abnormal vertebral segmentation in spondylocostal
dysostosis. Hum Mol Genet. 20:905–916. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hiroshima K, Iyoda A, Shida T, Shibuya K,
Iizasa T, Kishi H, Tanizawa T, Fujisawa T and Nakatani Y:
Distinction of pulmonary large cell neuroendocrine carcinoma from
small cell lung carcinoma: A morphological, immunohistochemical,
and molecular analysis. Mod Pathol. 19:1358–1368. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Myong NH: Thyroid transcription factor-1
(TTF-1) expression in human lung carcinomas: Its prognostic
implication and relationship with expressions of p53 and Ki-67
proteins. J Korean Med Sci. 18:494–500. 2003. View Article : Google Scholar : PubMed/NCBI
|
